Read by QxMD icon Read

Endocrine, Metabolic & Immune Disorders Drug Targets

Antara Banerjee, Marco Scarpa, Surajit Pathak, Patrizia Burra, Giacomo Carlo Sturniolo, Francesco Paolo Russo, Ram Murugesan, Renata D'Incà
BACKGROUND AND AIMS: Sexual functions are sometimes adversely affected by the therapeutic drugs delivered for treating IBD. Much attention has been focused on pregnancy/sexual issues in women. Relatively less attention has been poured in to address this issue in men. This systematic review assesses the drugs having potential detrimental effects on fertility in men. METHODS: Three databases were searched by two researchers independently for potentially relevant publications between 1964 to 2015 and 249 papers were retrieved...
March 12, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Vincenzo Fiore, Antonia De Rosa, Paolo Falasca, Massimo Marci, Edoardo Guastamacchia, Brunella Licchelli, Vito Angelo Giagulli, Giovanni De Pergola, Antonella Poggi, Vincenzo Triggiani
Background In the last decades both diabetes mellitus and Alzheimer's disease are constantly increasing. Affected individuals, therefore, represent an enormous problem for society, governments and global organizations. These diseases are usually considered as independent conditions, but increasing evidence shows that there are links between these two disorders. OBJECTIVE: In this review, we analyzed common features present in Alzheimer's disease and diabetes mellitus, showing how these two diseases are strictly correlated each other...
March 11, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Paula Domenech-Cebrián, Omar Cauli
BACKGROUND: Many neurological disorders lead to institutionalization and can be accompanied in their advanced stages by functional impairment, and progressive loss of mobility, and cognitive alterations. OBJECTIVE: We analyzed the relationship between functional impairment and cognitive performance and its related subdomains in individuals with Parkinson's disease, Alzheimer's disease accompanied by motor dysfunction, and with other neurological disorders characterized by both motor and cognitive problems...
March 10, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Amparo Tatay-Manteiga, Vicent Balanzá-Martínez, Giovana Bristot, Rafael Tabarés-Seisdedos, Flavio Kapczinski, Omar Cauli
AIMS: Oxidative stress is increased during the acute phases of bipolar disorder (BD). Our aim here was to analyze oxidative stress biomarkers in patients with BD during euthymia and their siblings. METHOD: Cross-sectional study perfomed in euthymic patients with BD-I (n=48), unaffected siblings (n=23) and genetically unrelated healthy controls (n=21). Protein carbonyl content (PCC), total anti-oxidant capacity (TRAP), lipid peroxidation (TBARS) and uric acid were measured as biomarkers of oxidative stress in blood...
March 7, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Megna Marisa, Marvulli Riccardo, Farì Giacomo, Gallo Giulia, Dicuonzo Franca, Fiore Pietro, Ianieri Giancarlo
BACKGROUND AND OBJECTIVE: Spasticity (most common disability in upper motor neuron syndrome or UMNS) caused an inability of patients' activities daily and quality of life. One of the promising methods nowadays, but still not widely used in everyday practice, for spasticity reduction is extracorporeal shock wave. Aim of this study was to evaluate objective clinical effects of combined treatment botulinum toxin type A and radial Extracorporeal Shock Wave Therapy in spasticity post stroke...
March 5, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Alireza Derakhshan, Mahmood Khodadoost, Mostafa Ghanei, Latif Gachkar, Homa Hajimahdipour, Ali Taghipour, Jaleh Yousefi, Maryam Khoshkhui, Farahzad Jabbari Azad
INTRODUCTION: Current treatment options for Allergic Rhinitis (AR) may have their own limitations and side effects. This study aimed to investigate the effects of Ma-al-Shaeer (MS), a novel natural formulation based on Hordeum vulgare, in treatment of AR compared with Fexofenadine (FX). METHOD: A total of 77 patients with AR were divided into two groups: MS group (n=38) and FX group (n=39). The first group received 15 mg of dried MS powder, and the second group received 60 mg of FX twice daily for 14 days...
March 5, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Ozlem Ozmen, Senay Topsakal
OBJECTIVE: The aim of this study was to examine pancreatic pathology and the prophylactic effects of pregabalin in lipopolysaccharide (LPS) induced sepsis model in aged rats. METHODS: Twenty-four female, one-year-old, Wistar Albino rats were assigned to three groups; Group I (control), Group II (study group: 5mg/kg LPS intraperitoneal, single dose) and Group III (treatment group: 5mg/kg LPS + 30 mg/kg oral pregabalin one hour before LPS). Animals were sacrificed by exsanguination 6 hours after LPS administration...
March 5, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Yenny, Sonar S Panigoro, Denni J Purwanto, Adi Hidayat, Melva Louisa, Rizka Andalusia, Rianto Setiabudy
BACKGROUND: Tamoxifen (TAM) is a frequently used hormonal prodrug for patients with breast cancer that needs to be activated by cytochrome P450 2D6 (CYP2D6) into Zusammen-endoxifen (Z-END). OBJECTIVE: The purpose of the study was to determine the association between CYP2D6*10 (c.100C>T) genotype and attainment of the plasma steady state Z-END minimal threshold concentration (MTC) in Indonesian women with breast cancer. METHODS: A cross-sectional study was performed in 125 ambulatory patients with breast cancer consuming TAM at 20 mg/day for at least 4 months...
March 5, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Sara M Ahmed, Dina Johar, Mohamed Medhat Ali, Nagwa El-Badri
BACKGROUND: Diabetes mellitus is a metabolic disorder that is characterized by impaired glucose tolerance resulting from defects in insulin secretion, insulin action, or both. Epigenetic modifications, which are defined as inherited changes in gene expression that occur without changes in gene sequence, are involved in the etiology of diabetes. METHODS: In this review, we focused on the role of DNA methylation and protein misfolding and their contribution to the development of both type 1 and type 2 diabetes mellitus...
March 5, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Pragya Tiwari, Ashish Katyal, Mohd Faheem Khan, Ghulam Md Ashraf, Khurshid Ahmad
BACKGROUND: Diabetes, defined as chronic metabolic syndrome, exhibits global prevalence and phenomenal rise worldwide. The rising incidence accounts for global health crisis, demonstrating a profound effect on low and middle-income countries, particularly people with limited healthcare facilities. METHODS: Highlighting the prevalence of diabetes and its socio-economic implications on the population across the globe, the article aimed to address the emerging significance of computational biology in drug designing and development, pertaining to identification and validation of lead molecules for diabetes treatment...
March 4, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Abdulmajeed Abdullah Albarrak, Bhupinder Singh Romana, Suleyman Uraz, Mohamad Hasan Yousef, Alhareth Al Juboori, Veysel Tahan
BACKGROUND: The rising incidence of Clostridium difficile infection (CDI) in the general population has been recognized by health care organizations worldwide. The emergence of hypervirulent strains has made CDI more challenging to understand and treat. Inflammatory bowel disease (IBD) patients are at higher risk of infection, including CDI. OBJECTIVE: A diagnostic approach for recurrent CDI has yet to be validated, particularly for IBD patients. Enzyme immunoassay (EIA) for toxins A and B, as well as glutamate dehydrogenase EIA, are both rapid testing options for the identification of CDI...
March 1, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Fenqin Chen, Guozhu Wei, Yang Zhou, Xiaoyu Ma, Qiuyue Wang
Background Although the pathogenetic mechanism of diabetic kidney disease (DKD) has not been elucidated, an inflammatory mechanism may be a potential contributor. Monocyte chemotactic protein-1(MCP-1) is suggested to be implicated in the development of DKD by playing a role in infiltration of monocyte/macrophage.The aim of this study was to investigate the expression of MCP-1 under high glucose conditions, as well as the effects of microRNA-192 (miR-192) under these conditions, and to study the regulatory mechanism of MCP-1 in DKD...
March 1, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Tareq Hossan, Shoumik Kundu, Sayeda Sadia Alam, Sankari Nagarajan
BACKGROUND AND OBJECTIVE: Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder. Pancreatic β-cell dysfunction and insulin resistance are the most common and crucial events of T2DM. Increasing evidences suggest the association of epigenetic modifications with pathogenesis of T2DM through the changes in important biological processes including pancreatic β-cell differentiation, development and maintenance of normal β-cell function. Insulin sensitivity by the peripheral glucose-up taking tissues are also changed by the altered epigenetic mechanisms...
March 1, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Yunjuan Zhao, Yunliang Xie, Wangen Li
BACKGROUND: Type 1 diabetes is a T cell mediated autoimmune disease. Interferon γ plays a critical role in the pathogenesis of type 1 diabetes. Signal transducer and activator of transcription transduces type I interferon cytokines in T cells, leading to Th1 cell differentiation and production of interferon γ. Recent studies suggest that liraglutide reduces plasma concentration of C-reative protein in patients with type 1 diabetes and protects β cell function in the non-obese diabetic mouse...
February 28, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Rosy Vennila, Raja Sundari Meenakshi Sundaram, Sakthivel Selvaraj, Surajit Pathak, Secunda Rupert, Surendran Rajagopal
BACKGROUND: Mesenchymal stem cells (MSCs) are highly preferred in clinical therapy for repair and regeneration of diseased tissues for their multipotent properties. Conventionally, MSCs have been cultured in media supplemented with animal derived serum, however, it is ideal to expand MSCs in media containing supplements of human origin for clinical therapy. Currently, a number of human derived products are being studied as an alternative to animal sources. Amongst these, platelet lysate (PL) has gained interest in the culture of MSCs without affecting their phenotypic property...
February 26, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Xuan Wang, Xiaoqing Shao, Xinhao Liu, Qiu Qin, Jian Xu, Jin An Zhang
OBJECTIVE: Hashimoto's Thyroiditis (HT) is an autoimmune disease, characterized by chronic inflammation of the thyroid gland with unknown etiologies. Recently, interlukin-33/ST2 (IL-33/ST2) pathway has been revealed its participation in the process of several autoimmune diseases. In this study, the role of IL-33/ST2 pathway in the development of HT is investigated. METHODS: The levels of plasma IL-33, sST2 and the frequency of circulating CD4+ST2L+T cells in 30 HT patients and 20 healthy controls were determined by enzyme-linked immunosorbent assay (ELISA) and flow cytometry respectively...
February 26, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Reza Yazdani, Zahra Hamidi, Fateme Babaha, Gholamreza Azizi, Saba Fekrvand, Hassan Abolhassani, Asghar Aghamohammadi
BACKGROUND AND OBJECTIVE: APDS [Activated phosphoinositide 3-kinase (PI3K) δ Syndrome] is a newly found special form of primary immunodeficiency caused by mutations in genes encoding PI3Kδ subunits and over-activation of the PI3K signaling pathway. Gain-of-function and loss-of-function mutations in PIK3CD (encoding P110δ) and PIK3R1 (encoding p85α, p55α and p50α) lead to APDS1 and APDS2, respectively. The subsequent irregular PI3K downstream signaling cascade is associated with abnormalities in B cells and T cells and the consequent heterogeneous clinical manifestations including respiratory tract infections, autoimmunity, lymphoproliferation and not to mention primary antibody deficiency...
February 24, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Ya Liu, Jian Kang, Hong Gao, Xiyu Zhang, Jun Chao, Guangming Gong, Haipo Yuan, Chunguang Xie
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a world-wide metabolic disease with no cure from drugs and treatment. In China, The traditional Chinese medicine (TCM) herbal formulations have been used to treat T2DM for centuries. METHODS: In this study, we proposed a formula called ShenQi compound (SQC), which has been used in clinical therapeutics in China for several years. We evaluated the effect of SQC in a spontaneous diabetic rat model (GK rats) by detecting a series of blood indicators and performing histological observations...
February 24, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Chima A Egedigwe-Ekeleme, Ifeoma I Ijeh, Polycarp N Okafor, Chinedum O Eleazu, Uchenna O Egedigwe
BACKGROUND: No study till date has reported the effect of fractions of Vernonia amygdalina on obese animals as a way of developing novel drugs for the treatment of obesity. OBJECTIVES: To investigate the effect of fractions (F1-F5) from methanol extract of Vernonia amygdalina (VA) on high fat diet induced obese rats. METHOD: Methanol extract of VA was fractionated using a column. After twelve weeks of obesity induction, forty-eight male wistar rats were randomly distributed into eight groups...
February 22, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Mohamed M Aboelnaga, Eman H Eladawy, Maha M Elshafei, N Abdullah, M El Shaer
OBJECTIVE: We aimed in the current study to: 1) evaluate and compare metabolic and anthropometric profile in female patients with newly diagnosed prolactin secreting adenoma versus female idiopathic hyperprolactinemic patients 2) compare the effects of one year cabergoline therapy on the metabolic profile and anthropometric parameters (by using visceral adiposity index as index for evaluation of adipose tissue dysfunction) in female patients with prolactin secreting pituitary adenoma to female idiopathic hyperprolactinemic patients...
February 18, 2019: Endocrine, Metabolic & Immune Disorders Drug Targets
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"